Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Fares Bassil(Centre National de la Recherche Scientifique), Wassilios G. Meissner(Centre National de la Recherche Scientifique), Erwan Bézard(Centre National de la Recherche Scientifique), Pierre‐Olivier Fernagut(Inserm)
Cited by 223
Related Papers
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy
|Movement Disorders|2022|788
The natural history of multiple system atrophy: a prospective European cohort study
|The Lancet Neurology|2013|533
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
|The Lancet Neurology|2015|508